Significant reductions in disability index (HAQ-DI), fatigue (FACIT-F) (Table 9), and improvement in both the physical and mental health domains of the SF-36 were observed in patients treated with rituximab compared to patients treated with methotrexate alone (SF-36 Physical 5.8 vs.